


British National Formulary (BNF) 90
September 2025 edition
ISBN: 9780857114907
£79 Sterling RRP
The first choice for concise medicines information
Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.
Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.
Extensive content updates in the BNF 90 edition include:
New monographs for:
Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy
Anzupgo® [delgocitinib] for treatment of moderate-to-severe hand eczema
Briumvi® [ublituximab] for treatment of multiple sclerosis
Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy
Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome
Kisunla® [donanemab] for treatment of mild cognitive impairment or mild dementia in Alzheimer’s disease
Lunivia® [eszopiclone] for short-term treatment of insomnia
Vafseo® [vadadustat] for treatment of symptomatic anaemia associated with chronic kidney disease in patients on chronic maintenance dialysis
Winlevi® [clascoterone] for treatment of acne vulgaris
Yorvipath® [palopegteriparatide] for treatment of chronic hypoparathyroidism
MHRA advice on:
Fezolinetant: risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
Prolonged-release opioids: removal of indication for relief of post-operative pain
Sodium valproate and Valproic acid: new advice for male patients already taking these
Other significant changes include updated guidance on:
Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice
Apixaban: update to structure of dosing for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor
Asthma, chronic: updated guidance on management
Bempedoic acid: new indication and dose for established or at high-risk of atherosclerotic cardiovascular disease
Bimekizumab: new indication and dose for hidradenitis suppurativa
Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms, and Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy
Cardiovascular disease risk assessment and prevention: updated guidance
Chloroquine: updated pregnancy and breast-feeding advice when used for rheumatic disease
Contraceptives, hormonal: inclusion of guidance for use of combined oral contraceptives for preventive treatment of ovarian cancer in at-risk females
Dupilumab: new indication and dose for chronic obstructive pulmonary disease
Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1 infection
Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice
Malaria prophylaxis: updated guidance
Naltrexone hydrochloride: new indication and dose for gambling-related harm
Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change of Apexxnar® to Prevenar 20®
Sepsis: updated guidance on management
Smoking cessation: updated drug treatment guidance
Sympathomimetics: updated guidance for septic shock
Tuberculosis: updated guidance for multi-drug resistant tuberculosis
Wegovy® (semaglutide): new indication and dose for cardiovascular risk reduction
BNF is published jointly by BMJ Group and Pharmaceutical Press.
September 2025 edition
ISBN: 9780857114907
£79 Sterling RRP
The first choice for concise medicines information
Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.
Practical and evidence-based, BNF is an integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.
Extensive content updates in the BNF 90 edition include:
New monographs for:
Agamree® [vamorolone] for treatment of Duchenne muscular dystrophy
Anzupgo® [delgocitinib] for treatment of moderate-to-severe hand eczema
Briumvi® [ublituximab] for treatment of multiple sclerosis
Duvyzat® [givinostat] for treatment of Duchenne muscular dystrophy
Joenja® [leniolisib] for treatment of activated phosphoinositide 3-kinase delta syndrome
Kisunla® [donanemab] for treatment of mild cognitive impairment or mild dementia in Alzheimer’s disease
Lunivia® [eszopiclone] for short-term treatment of insomnia
Vafseo® [vadadustat] for treatment of symptomatic anaemia associated with chronic kidney disease in patients on chronic maintenance dialysis
Winlevi® [clascoterone] for treatment of acne vulgaris
Yorvipath® [palopegteriparatide] for treatment of chronic hypoparathyroidism
MHRA advice on:
Fezolinetant: risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
Prolonged-release opioids: removal of indication for relief of post-operative pain
Sodium valproate and Valproic acid: new advice for male patients already taking these
Other significant changes include updated guidance on:
Amphotericin B: review of indications and dose for liposomal preparations, as well as updates to directions for administration, breast-feeding, pregnancy, cautions, and monitoring advice
Apixaban: update to structure of dosing for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor
Asthma, chronic: updated guidance on management
Bempedoic acid: new indication and dose for established or at high-risk of atherosclerotic cardiovascular disease
Bimekizumab: new indication and dose for hidradenitis suppurativa
Budesonide with formoterol (DuoResp Spiromax® 160 micrograms/4.5 micrograms, and Fobumix® 160/4.5 Easyhaler): new indication and dose for mild asthma, reliever therapy
Cardiovascular disease risk assessment and prevention: updated guidance
Chloroquine: updated pregnancy and breast-feeding advice when used for rheumatic disease
Contraceptives, hormonal: inclusion of guidance for use of combined oral contraceptives for preventive treatment of ovarian cancer in at-risk females
Dupilumab: new indication and dose for chronic obstructive pulmonary disease
Emtricitabine with tenofovir alafenamide: new indication and dose for pre-exposure prophylaxis of HIV-1 infection
Hydroxychloroquine sulfate: updated pregnancy and breast-feeding advice
Malaria prophylaxis: updated guidance
Naltrexone hydrochloride: new indication and dose for gambling-related harm
Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change of Apexxnar® to Prevenar 20®
Sepsis: updated guidance on management
Smoking cessation: updated drug treatment guidance
Sympathomimetics: updated guidance for septic shock
Tuberculosis: updated guidance for multi-drug resistant tuberculosis
Wegovy® (semaglutide): new indication and dose for cardiovascular risk reduction
BNF is published jointly by BMJ Group and Pharmaceutical Press.